We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NEW YORK, NY -- (Marketwire) -- 08/15/12 -- MNSquotes.com offers free real-time market quotes and level II access along with breaking news from leading North American stock exchanges. MNS Quotes...
SAN ANTONIO, TX -- (Marketwire) -- 07/10/12 -- OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer...
SAN ANTONIO, TX -- (Marketwire) -- 11/28/11 -- OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer...
OncoVista Innovative Therapies, Inc. (OTCBB:OVIT) reported that it has initiated an additional safety study of OVI-117 in a 2nd animal species. “OncoVista is moving ahead...
LOS ANGELES, CA -- (Marketwire) -- 05/11/11 -- An article in this week's BioTuesdays profiled a quiet biotech firm that may begin to make some noise via key acquisitions. Their focus is deep in...
OncoVista Innovative Therapies, Inc., (OTCBB:OVIT) reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more...
OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a high-growth global biopharmaceutical company commercializing diagnostic tests for metastatic tumors, as well as developing...
AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a high-growth global biotech company developing proprietary, leading-edge early detection and...
OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable...
OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | -0.0001 | -50 | 0.0002 | 0.0002 | 0.0001 | 6868 | 0.00012719 | CS |
12 | 9.9E-5 | 9900 | 1.0E-6 | 0.0002 | 1.0E-6 | 4578 | 0.00012719 | CS |
26 | 0 | 0 | 0.0001 | 0.0002 | 1.0E-6 | 4767 | 4.645E-5 | CS |
52 | 9.9E-5 | 9900 | 1.0E-6 | 0.0002 | 1.0E-6 | 24193 | 9.222E-5 | CS |
156 | 9.9E-5 | 9900 | 1.0E-6 | 0.0002 | 1.0E-6 | 22796 | 0.00013174 | CS |
260 | -0.0151 | -99.3421052632 | 0.0152 | 0.137 | 1.0E-6 | 36897 | 0.03694393 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions